Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Medicover: Interim report April-June 2024
First half First half REVENUE AND EARNINGS Definition and reconciliation of alternative performance measures are available atwww.medicover.com/financial-information. 1) LTM: last twelve months (1 July 2023-30 June 2024) CEO STATEMENT We continue to deliver strong organic revenue growth and see continued strong momentum in our core markets, with high demand across divisions and geographies, especially inPoland. The margin expansion and strong operating cash...
PR Newswire
25/07/2024
Financière de Tubize - 2024 half-year financial report
Half-year financial report 2024 Regulated information 25 July 2024The board of directors of Financière de Tubize has established the 2024 half-year report. This report is available on the websitewww.financiere-tubize.be. Profit for the first half of 2024: € 92.9 million (€ 91.1 million in 2023, + 2.1%),Dividend received from UCB: € 95.9 million (€ 1.36 per share, an increase of 2.3% compared to the previous year),2023 Dividend paid to Financière de Tubize's shareholders in 2024 of €...
Nasdaq GlobeNewswire
25/07/2024
Indivior Announces Q2 2024 Financial Results
Webcast link: https://edge.media-server.com/mmc/p/jpgy4cd9Participants may access the presentation telephonically by registering with the following link: https://register.vevent.com/register/BIdf08b662a5f24248bf5f8677f59ef713 Webcast link:https://edge.media-server.com/mmc/p/jpgy4cd9Participants may access the presentation telephonically by registering with the following link:https://register.vevent.com/register/BIdf08b662a5f24248bf5f8677f59ef713 (Registrants will have an option to be...
PR Newswire
25/07/2024
Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024…
Sanofi Q2: strong performance with 10% sales growth; 2024 guidance upgradedParis, July 25, 2024Q2 sales growth of 10.2% at CER and business EPS (1)of €1.73Dupixent sales up 29.2% to €3,303 million; target of ~€13 billion in 2024 unchangedPharma launches up 80.4% to €689 million, led by ALTUVIIIO, Nexviazyme, Rezurock, and SarclisaVaccines sales -4.8% due to COVID-19 sales in 2023Opella (former Sanofi Consumer Healthcare) up 9.6%, driven by the Qunol acquisition...
Nasdaq GlobeNewswire
25/07/2024
Nicox Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of…
Press ReleaseNicox Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of NCX 470 Recruitment continues in China, on track for topline results in H2 2025 NCX 470 demonstrated robust efficacy and safety in topline results from first Phase 3 trial, Mont BlancJuly 25, 2024 – release at 7:30 am CET Sophia Antipolis, France Nicox SA(Euronext Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced the recruitment and...
Nasdaq GlobeNewswire
25/07/2024
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in…
Group saleswere up by 5% 1at constant exchange rates (CER) (stable in CHF) in the first half, driven by the high demand for both our medicines and diagnostics; excluding COVID-19-related products, sales increased by 8%Group salesgrowth accelerated to 9% (7% in CHF) in the second quarter as the decline in COVID-19-related sales no longer had an impact on overall sales Pharmaceuticals Divisionsalesrose by 5% in the first half; strong growth of 8% in thebase business2...
Nasdaq GlobeNewswire
25/07/2024
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat…
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz launches biosimilar Pyzchiva®(ustekinumab) across Europe, to treat chronic inflammatory diseasesLaunch across Europe, starting today, strengthens well-established Sandoz immunology portfolio in Europe, leveraging existing footprintPyzchiva® first ustekinumab biosimilar to launch in Europe with all reference medicine strengths, including 130mg vial initiation dose for Crohn's diseasePyzchiva® to treat...
Nasdaq GlobeNewswire
25/07/2024
Ipsen delivers strong results in the first half of 2024, progresses on launches…
PARIS, FRANCE, 25 July 2024 -Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the first half of 2024.Business highlightsU.S. regulatory approvals and launches of Onivyde ®(irinotecan) in first-line pancreatic cancer and Iqirvo ®(elafibranor) in second-line primary biliary cholangitis, respectivelyIn-licensing of tovorafenib outside the U.S.: an attractive addition to our Oncology pipeline...
Nasdaq GlobeNewswire
25/07/2024
Idorsia announces financial results for the first half 2024
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 25, 2024Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2024. Business highlights Viatris collaboration:Global research and development collaboration, focused on the development and commercialization of two innovative compounds, selatogrel and cenerimod. Adapted governance : On June 13, 2024, Jean-Paul Clozel retired from his position as CEO of Idorsia and was elected as...
Nasdaq GlobeNewswire
25/07/2024
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to…
Ipsen secures ex-U.S. regulatory and commercial rights to tovorafenib for most common childhood brain tumor, pediatric low-grade glioma (pLGG), and any future indicationsOJEMDA™ (tovorafenib) is the first FDA-approved treatment for relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or V600 mutation, following the pivotal Phase II trial, FIREFLY-1Day One receives approximately $111 million upfront in cash and equity investment with up to approximately $350 million in...
Nasdaq GlobeNewswire
25/07/2024
CARBIOS and Nouvelles Fibres Textiles cooperate to develop the French polyester…
CARBIOS and Nouvelles Fibres Textiles work together towards a contract to supply post-consumer and post-industrial polyester textiles for the world's first PET biorecycling plantThe 5-year contract covers a volume of 5,000 tons per year of prepared polyester textiles from end 2026The two companies combine their innovations to establish a complete ecosystem in France for textile circularityClermont-Ferrand (France), Thursday 25 July 2024 (6.45am CEST). CARBIOS,...
Nasdaq GlobeNewswire
25/07/2024
Spineway a Gold Sponsor at the SILACO Congress in Mexico - Organization of a…
Press release Ecully, July 24, 2024 – 6 p.m. Spineway a Gold Sponsor at the SILACO Congress in Mexico Organization of a special event with Latin American distributors The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, is taking part in theSociedad Iberolatinoamericana de Columna(SILACO) Congress in Mexico from July 24 to 27, 2024 with two local partners, Spinemed and Mava. As a Gold Sponsor of this major event in Latin...
Nasdaq GlobeNewswire
24/07/2024
Oxurion Announces Results on the Extraordinary General Meeting (EGM) of 24 July…
Oxurion Announces Results on the Extraordinary General Meeting (EGM) of 24 July 2024Leuven, BELGIUM – 24 July, 2024 – 06.00 PM CET– Oxurion NV(Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, held an Extraordinary General Meeting on July 24, 2024. The shareholders approved all items on the agenda of the Extraordinary General Meeting.All documents pertaining to the Extraordinary General Meeting held on July 24, 2024, can be consulted on Oxurion's...
Nasdaq GlobeNewswire
24/07/2024
Myocarditis Treatment Market Size is Projected to Reach US$ 2.7 billion…
A surge in clinical trials and research activities aimed at understanding the pathophysiology of myocarditis and developing targeted treatments is observed. Advances in regenerative medicine, including stem cell therapy, offer promising avenues for myocarditis treatment by promoting cardiac tissue repair and regeneration. A surge in clinical trials and research activities aimed at understanding the pathophysiology of myocarditis and developing targeted treatments is observed. Advances in...
PR Newswire
24/07/2024
Naltrexone Market Surges to USD 30.8 Billion by 2034 | Driven by Increasing…
The global naltrexone market is witnessing substantial growth, driven by several key factors. Naltrexone, a medication primarily used in the treatment of alcohol dependence and opioid addiction, plays a crucial role in managing substance abuse disorders and related conditions. The global naltrexone market is witnessing substantial growth, driven by several key factors. Naltrexone, a medication primarily used in the treatment of alcohol dependence and opioid addiction, plays a crucial role in...
PR Newswire
24/07/2024
ADVANCION AWARDED ECOVADIS GOLD SUSTAINABILITY RATING FOR SIXTH YEAR
"We are incredibly proud to once again earn the EcoVadis Gold Medal for sustainability performance in 2024," said David Neuberger, President and Chief Executive Officer. "This recognition not only reflects our unwavering commitment to sustainable practices, but it is also a testament to the dedication of our team to creating a positive impact on the environment and society. Achieving this milestone is crucial as it independently validates our efforts to operate responsibly as well…
PR Newswire
24/07/2024
Dental 3D Printing Market: CAD/CAM Technologies Propel Growth to USD 15.9…
Download a detailed overview:https://www.skyquestt.com/sample-request/dental-3d-printing-market Download a detailed overview: https://www.skyquestt.com/sample-request/dental-3d-printing-market Dental 3D Printing Market Overview: Segments covered in Dental 3D Printing Market are as follows: Request Free Customization of this report: https://www.skyquestt.com/speak-with-analyst/dental-3d-printing-market Growing Technological Advancements in 3D Printing Used for Dental...
PR Newswire
24/07/2024
Lipophilic Dyes Market to Reach USD 2.8 Billion by 2034, Growing at 7.0% CAGR…
The trend of utilizing fluorescent dyes for imaging and diagnostic purposes is on the rise due to their high sensitivity and specificity, which enhances the accuracy of research and diagnostic outcomes. The integration of AI and machine learning in imaging technologies is improving the efficiency of lipophilic dyes in research and diagnostics, leading to higher adoption rates. The trend of utilizing fluorescent dyes for imaging and diagnostic purposes is on the rise due to their high...
PR Newswire
24/07/2024
Melanoma Therapeutics Market to Reach USD 19.2 Billion by 2034 | Surge in R&D…
With the growing prevalence of carcinogenic disorders, the demand for relevant therapies and treatments has surged. The rising demand for related medications has elevated, driving prospects for leading players in the competitive landscape. With the growing prevalence of carcinogenic disorders, the demand for relevant therapies and treatments has surged. The rising demand for related medications has elevated, driving prospects for leading players in the competitive landscape. Melanoma cells...
PR Newswire
24/07/2024
Functional Endoscopic Sinus Surgery Market worth $1.7 billion by 2029 driven by…
Browse in-depth TOC on "Functional Endoscopic Sinus Surgery Market" Browse in-depth TOC on "Functional Endoscopic Sinus Surgery Market" 356 - Tables 49 - Figures 273 - Pages Medtronic plc ( Ireland ): Market Leader in Functional Endoscopic Sinus Surgery Medtronic plc ( Ireland ) led the Functional Endoscopic Sinus Surgery (FESS) market in 2023, thanks to its robust global distribution networks acrossNorth America,Europe,Asia Pacific,Latin America, and the...
PR Newswire
24/07/2024
GLP-1 Market Size to Reach USD 95.4 Billion with a CAGR of 10.3% from 2024 to…
Free Download the Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2592 Free Download the Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2592 Glucagon-like peptide-1 (GLP-1) is a gut-produced hormone essential for regulating blood sugar levels and appetite. GLP-1 receptor agonists are medications that activate the GLP-1 receptor, resulting in several beneficial effects, including enhancing insulin secretion from...
PR Newswire
24/07/2024
InterSystems TrakCare and InterSystems IRIS for Health to underpin deployment of…
Additionally, by the end of 2024 InterSystems IRIS® for Health will centralize NEOM's clinical application data to facilitate the development of innovative health programs. InterSystems IRIS for Health is a comprehensive, cloud-first digital health development platform that provides all the building blocks needed for Machine Learning and to work with practically any healthcare data standard, including HL7® FHIR®. Additionally, by the end of 2024 InterSystems IRIS® for Health will centralize...
PR Newswire
24/07/2024
iHerb Welcomes Martha Stewart Wellness to its Global Assortment
The new products from Martha Stewart Wellness use all-natural, sustainably sourced ingredients and are free from any artificial additives. The product line was designed with versatility and ease-of-use by offering supplements that provide a range of benefits and can be used to support a healthy lifestyle. The products are meticulously crafted to nurture health and well-being, a great complement to any wellness journey. The new products from Martha Stewart Wellness use all-natural, sustainably...
PR Newswire
24/07/2024
'HOT BOY SUMMER': SUN PROTECTION 'UNMASCULINE' FOR A THIRD OF MEN, LEAVING THEM…
Love Island pranksters, Tom Clare and Casey O'Gorman, have teamed up with PIZ BUIN® to launch the brand-new 'Hiz Buin' campaign, highlighting the importance of sun safety following research that revealed - men are far less likely to use suncream than women. "On Love Island, we spent most of our time out in the sun. We never really thought much about it if we got a bit red, and it was always funny when someone got burnt. We didn't think about skin damage. The girls were the opposite, they…
PR Newswire
24/07/2024
Altri Comunicati
